(Q44533914)

English

Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies

scientific article published in August 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

phase III clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

David S. Alberts

6

object named as

David S Alberts

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

Michael A Gold

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Joan L Walker

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Jonathan S Berek

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Alton V Hallum

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Dava J Garcia

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

language of work or name

0 references

publication date

1 August 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

90

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

325-330

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II trials of WR-2721 and cis-platinum

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of WR-2721 and carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The modification of melphalan toxicity in tumor bearing mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR2721)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900319-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-8258(03)00319-6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

release_inesvy5k35ahhm5c6fupdtgeei

1 reference

https://api.fatcat.wiki/v0/release/inesvy5k35ahhm5c6fupdtgeei

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44533914&oldid=2076555599"